Glioblastoma multiforme (GBM) is one of the most common malignant brain tumors with poor prognosis and poor response to current standard treatment. This article retrospectively analyzed the clinical data of a 34-year-old patient with GBM who received tumor treating fields (TTFields) combined with chemoradiotherapy, in order to explore the efficacy of TTFields combined with chemoradiotherapy in patients with GBM who did not receive surgical treatment. The patient had a high tumor load, had multiple lesions at the time of diagnosis, and had no indications for surgery. After TTFields treatment combined with chemoradiotherapy, it showed a good curative effect, with obvious improvement of symptoms. The progression-free survival (PFS) was 9 months and the overall survival (OS) was 27 months. As a novel therapeutic method, TTFields has a good synergistic effect with current cancer treatment strategies and shows tremendous potential for development. However, this technology is still in its early stages that require continuous research and improvement to fully realize its potential.

1.Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020[J]. Neuro Oncol, 2023, 25(12 Suppl 2): iv1-iv99. DOI: 10.1093/neuonc/noad149.

2.Horbinski C, Nabors LB, Portnow J, et al. NCCN guidelines® insights: central nervous system cancers, version 2.2022[J]. J Natl Compr Canc Netw, 2023, 21(1): 12-20. DOI: 10.6004/jnccn.2023.0002.

3.Kutuk T, Atak E, La Rosa A, et al. Tumor treating fields: narrative review of a promising treatment modality for cancer[J]. Chin Clin Oncol, 2023, 12(6): 64. DOI: 10.21037/cco-23-82.

4.Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial[J]. JAMA, 2017, 318(23): 2306-2316. DOI: 10.1001/jama.2017. 18718.

5.Miller R, Song A, Ali A, et al. Scalp-sparing radiation with concurrent temozolomide and tumor treating fields (SPARE) for patients with newly diagnosed glioblastoma[J]. Front Oncol, 2022, 12: 896246. DOI: 10.3389/fonc.2022.896246.

6.Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10): 987-996. DOI: 10.1056/NEJMoa043330.

7.Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247. DOI: 10.1016/j.ejca.2008.10.026.

8.宋昆, 陈灵朝, 秦智勇. 肿瘤电场治疗脑胶质瘤的临床研究进展[J]. 临床神经外科杂志, 2024, 21(1): 1-5. [Song K, Chen LC, Qin ZY. Clinical research progress in treatment of glioma with tumor treating fields[J]. Journal of Clinical Neurosurgery, 2024, 21(1): 1-5.] DOI: 10.3969/j.issn.1672-7770.2024.01.001.

9.Voloshin T, Kaynan N, Davidi S, et al. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy[J]. Cancer Immunol Immunother, 2020, 69(7): 1191-1204. DOI: 10.1007/s00262-020-02534-7.

10.Karanam NK, Ding L, Aroumougame A, et al. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: implications for cancer therapy[J]. Transl Res, 2020, 217: 33-46. DOI: 10.1016/j.trsl.2019.10.003.

11.Tanzhu G, Chen L, Xiao G, et al. The schemes, mechanisms and molecular pathway changes of tumor treating fields (TTFields) alone or in combination with radiotherapy and chemotherapy[J]. Cell Death Discov, 2022, 8(1): 416. DOI: 10.1038/s41420-022-01206-y.

12.Chang E, Patel CB, Pohling C, et al. Tumor treating fields increases membrane permeability in glioblastoma cells[J]. Cell Death Discov, 2018, 4: 113. DOI: 10.1038/s41420-018-0130-x.

13.Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields[J]. Cancer Res, 2004, 64(9): 3288-3295. DOI: 10.1158/0008-5472.can-04-0083.

14.Kirson ED, Dbalý V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors[J]. Proc Natl Acad Sci USA, 2007, 104(24): 10152-10157. DOI: 10.1073/pnas.0702916104.

15.Tran DD, Ghiaseddin AP, Chen DD, et al. Final analysis of 2-THE-TOP: a phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma[J]. Journal of Clinical Oncology, 2023, 41(16 suppl). DOI: 10.1200/JCO.2023.41.16_suppl.2024.

16.国家卫生健康委员会医政医管局. 脑胶质瘤诊疗规范(2018年版)[J]. 中华神经外科杂志, 2019, 35(3): 217-239. [National Health Commission Medical Administration Bureau. Guidelines for the diagnosis and treatment of glioma (2018 edition)[J]. Chinese Journal of Neurosurgery, 2019, 35(3): 217-239.] DOI: 10.3760/cma.j.issn.1001-2346.2019.03.001.

17.中国抗癌协会脑胶质瘤专业委员会, 胶质母细胞瘤的肿瘤电场治疗专家共识撰写组. 胶质母细胞瘤的肿瘤电场治疗专家共识[J]. 中华神经外科杂志, 2021, 37(11): 1081-1089. [Chinese Anti-Cancer Association Glioma Professional Committee, Glioblastoma Multiforme Tumor Treating Fields Expert Consensus Writing Group. Expert consensus on tumor treating fields for glioblastoma multiforme[J]. Chinese Journal of Neurosurgery, 2021, 37(11): 1081-1089.] DOI: 10.3760/cma.j.cn112050-20210406-00165.